Kokkotou, E.; Grapsa, D.; Papadopoulou, A.; Gaitanakis, S.; Bakakos, P.; Poulakou, G.; Moutsatsou, P.; Syrigos, K.
Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Cancers 2025, 17, 421.
https://doi.org/10.3390/cancers17030421
AMA Style
Kokkotou E, Grapsa D, Papadopoulou A, Gaitanakis S, Bakakos P, Poulakou G, Moutsatsou P, Syrigos K.
Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Cancers. 2025; 17(3):421.
https://doi.org/10.3390/cancers17030421
Chicago/Turabian Style
Kokkotou, Eleni, Dimitra Grapsa, Anna Papadopoulou, Stylianos Gaitanakis, Petros Bakakos, Garyfallia Poulakou, Paraskevi Moutsatsou, and Konstantinos Syrigos.
2025. "Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab" Cancers 17, no. 3: 421.
https://doi.org/10.3390/cancers17030421
APA Style
Kokkotou, E., Grapsa, D., Papadopoulou, A., Gaitanakis, S., Bakakos, P., Poulakou, G., Moutsatsou, P., & Syrigos, K.
(2025). Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Cancers, 17(3), 421.
https://doi.org/10.3390/cancers17030421
